Navigation Links
Additional Efficacy Data from Satraplatin SPARC Phase 3,Investigational Trial Presented at Annual Meeting of American,Urological Association

vements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Actual results could differ materially depending on a number of factors, and we caution investors not to place undue reliance on the forward-looking statements contained in this press release. In particular, there can be no guarantee that additional information relating to the safety, efficacy or tolerability of satraplatin may be discovered upon further analysis of data from the SPARC trial or analysis of additional data from other ongoing clinical trials for satraplatin. Furthermore, we cannot guarantee that satraplatin will be approved for marketing in a timely manner, if at all, by regulatory authorities nor that, if marketed, satraplatin will be a successful commercial product. We direct you to GPC Biotech's Annual Report on Form 20-F for the fiscal year ended December 31, 2005, Pharmion's Annual Report on Form 10-K for the fiscal year ended December 31, 2006, its most recent filings on Form 10-Q and other reports filed with the U.S. Securities and Exchange Commission for additional details on the important factors that may affect the future results, performance and achievements of either Pharmion or GPC Biotech. Forward-looking statements speak only as of the date on which they are made and neither Pharmion nor GPC Biotech undertakes any obligation to update these forward-looking statements, even if new information becomes available in the future.

Satraplatin has not yet been approved by the FDA in the U.S., the EMEA in Europe or any other regulatory authority and no conclusions can or should be drawn regarding its safety or effectiveness. Only the relevant regulatory authorities can determine whether satraplatin is safe and effective for the use(s) being investigated.

Taxotere(R) (docetaxel) is a registered trademark of Aventis Pharma S.A.

CONTACT: GPC Biotech AG - Martin Braendle, Director, Investor Relat
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
2. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
3. Additional Data on CombinatoRx Drug Candidates CRx-102 and CRx-139 Presented at EULAR
4. Further Statistical Analysis of the Recent Phase III trial on Lead Product M6G Shows Additional Benefits
5. Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting
6. Elixir Pharmaceuticals Presents Additional Preclinical Data Demonstrating the Potential of Ghrelin Antagonism to Regulate Metabolism, Body Weight and Glycemic Control
7. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
8. Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. New Study Results Provide Additional Data about Short- and Long-Term Use of Desvenlafaxine Succinate in the Treatment of Adults with Major Depressive Disorder
11. PTC Therapeutics Announces Additional Positive Interim Phase 2 Results of PTC124 in Duchenne Muscular Dystrophy
Post Your Comments:
(Date:10/19/2014)... Oct. 20, 2014 CTI BioPharma Corp. (CTI) ... report its third quarter 2014 financial results on Wednesday, ... financial markets. Following the announcement, members of the management ... the results and provide a general corporate update at ... event can be obtained as follows: Wednesday, ...
(Date:10/19/2014)... 2014 Große Pharmafirmen werden ... Problem dabei ist, dass große Pharmafirmen nicht willens ... teilen. Es war deshalb nicht einfach, ... umso mehr, dass es uns gelungen ist! Wir ... aufzuschreiben - mit einem Vorbehalt - einige haben ...
(Date:10/17/2014)... CHAPEL HILL, N.C. , Oct. 17, 2014 ... healthcare landscape, the Medical Affairs function has come ... metrics, allocating resources efficiently and managing globalization.  ... at Best Practices, LLC is dedicated to providing ... issues. The Medical Affairs Consortium is a service ...
Breaking Medicine Technology:CTI BioPharma to Report Third Quarter 2014 Financial Results on October 29, 2014 2Vergleichsbericht zu Pharma-Kühlketten und CRT 2Early Key Findings from the Medical Affairs Consortium Research 2
... Calif., Feb. 8, 2011 Anthera Pharmaceuticals, Inc. (Nasdaq: ... to treat serious diseases associated with abnormal auto-immune responses ... Rosania to the position of Vice President of Global ... for developing global regulatory strategies and managing all aspects ...
... 2011 Genomic Health, Inc. (Nasdaq: GHDX ) ... ended December 31, 2010. Total revenue for the ... with $149.5 million in 2009, an increase of 19 percent. ... 31, 2010, compared with $146.6 million in 2009.  Contract revenue ...
Cached Medicine Technology:Anthera Pharmaceuticals Names Lawrence Rosania as Vice President of Global Regulatory Affairs and Compliance 2Anthera Pharmaceuticals Names Lawrence Rosania as Vice President of Global Regulatory Affairs and Compliance 3Genomic Health Announces Year-End 2010 Financial Results, Provides 2011 Financial Outlook 2Genomic Health Announces Year-End 2010 Financial Results, Provides 2011 Financial Outlook 3Genomic Health Announces Year-End 2010 Financial Results, Provides 2011 Financial Outlook 4Genomic Health Announces Year-End 2010 Financial Results, Provides 2011 Financial Outlook 5Genomic Health Announces Year-End 2010 Financial Results, Provides 2011 Financial Outlook 6Genomic Health Announces Year-End 2010 Financial Results, Provides 2011 Financial Outlook 7Genomic Health Announces Year-End 2010 Financial Results, Provides 2011 Financial Outlook 8Genomic Health Announces Year-End 2010 Financial Results, Provides 2011 Financial Outlook 9
(Date:10/20/2014)... Indianapolis, IN (PRWEB) October 20, 2014 ... Quick Start, a secure cloud solution that enables ... advantage of the ultimate healthcare-specific customer relationship management ... to meet the unique needs of the healthcare ... healthcare experience for providers and patients by combining ...
(Date:10/20/2014)... AttorneyOne.com, a recognized authority on law, update the ... on Sit and Slim II . , The ... use Sit and Slim II because it contains Sibutramine ... weight loss product on various websites and possibly in some ... for safety reasons, can significantly increase blood pressure and/or pulse ...
(Date:10/20/2014)... October 20, 2014 National Teen Driver Safety ... the American Academy of Pediatrics (Ohio AAP, http://www.ohioaap.org ) ... encouraging parents of teen drivers to talk to their teens ... , Motor vehicle crashes are the leading cause of death ... involved in fatal crashes, and 859 (42%) of those teen ...
(Date:10/20/2014)... Houston plastic surgeon Dr. Christopher Patronella ... his innovative True Form Tummy Tuck® method ... faculty at The University of Texas Medical Branch ... a medical student. Patronella, who is a founding partner ... practices in Texas, The Aesthetic Center for Plastic ...
(Date:10/19/2014)... (PRWEB) October 19, 2014 Dr. Babatunde ... Fund, welcomes news of a ceasefire agreement that is ... than 200 girls who were kidnapped from the north-eastern ... languished in captivity long enough, and it is high ... communities," stated Dr. Osotimehin. , "We owe it to ...
Breaking Medicine News(10 mins):Health News:Healthcare Relationship Management (HRM) Leader hc1.com® Launches hc1® Quick Start™ 2Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Ohio AAP Promotes National Teen Driver Safety Week 2Health News:Plastic Surgeon Patronella Presents Artistically-Inspired Tummy Tuck Method to Future Generation of Plastic Surgeons in Texas 2
... -- Patients who are prescribed higher doses of opioid painkiller ... of death from overdose than those given lower doses, a ... the April 6 issue of the Journal of the ... who take opioid painkillers both as-needed and as regularly scheduled ...
... H5N1 avian influenza in endemic regions can largely be blamed ... poultry products and caged birds, and movement of wild birds ... outbreaks of avian influenza have suggested strong evidence of migratory ... distances. In a paper published last week in ...
... April 5 (HealthDay News) -- No doubt timed to coincide with ... detailing a trendy new diet made famous by the French is ... The Dukan Diet has sold more than 3 million ... is publishing the book here. Created by French physician Dr. ...
... Rockville, Md., April 5, 2011In the growing global battle ... of Medicines (PQM) program has launched a new, public ... stakeholders from countries in Africa, South America and Southeast ... access to the internet, the Medicines Quality Database (MQDB) ...
... TUESDAY, April 5 (HealthDay News) -- The inner ear can actually ... vibrations in the inner ear continue even after a sound has ... The study is published in the April 5 issue of ... the investigators found that after-vibrations in the inner ear were dependent ...
... Thousands of physicians, researchers and academics from around the ... Digestive Disease Week (DDW), the premiere scientific conference in ... Each day of the conference will feature ... gastrointestinal health issues, including: Does ...
Cached Medicine News:Health News:Patients on Higher Doses of Prescription Painkillers More Apt to Overdose 2Health News:Migratory birds, domestic poultry and avian influenza 2Health News:Migratory birds, domestic poultry and avian influenza 3Health News:Can the Dukan Diet Do It? 2Health News:Can the Dukan Diet Do It? 3Health News:New database to help track quality of medicines in global markets 2Health News:New database to help track quality of medicines in global markets 3
Castroviejo colibri tying forceps with 5 mm tips and 5 mm titanium coated platforms. Length 110 mm....
Tennant angled tying forceps with extra delicate smooth jaws, 6 mm tying platform, For 9-0 to 11-0 sutures. Overall length 108 mm....
Catalano straight tying forcep has 6 mm V-grove tying platform. Overall length 100 mm....
Kelman - McPherson tying forceps with serrated handle, platform 4 mm and overall length of 85 mm....
Medicine Products: